NCT00031629View on ClinicalTrials.gov

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2007

Conditions

Recurrent Uterine Corpus SarcomaUterine Corpus Leiomyosarcoma

Interventions

DRUG

Docetaxel

Given IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Gemcitabine Hydrochloride

Given IV

BIOLOGICAL

Pegfilgrastim

Given IV

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00031629 - Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | Biotech Hunter | Biotech Hunter